![Takehide Iwasa](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Takehide Iwasa
Director/Board Member at Karydo TherapeutiX, Inc.
Profile
Takehide Iwasa is currently a Director at Karydo TherapeutiX, Inc., Allgene, Inc., and Biomedica Solution KK.
He was previously a Director & General Manager-Sales at tella, Inc.
Takehide Iwasa active positions
Companies | Position | Start |
---|---|---|
Karydo TherapeutiX, Inc.
![]() Karydo TherapeutiX, Inc. Miscellaneous Commercial ServicesCommercial Services Karydo TherapeutiX, Inc. develops technologies to detect the earliest signs of diseases. Its proprietary technology includes “iOrgans Technology.” This technology consists of three sub-technologies: Reverse-iOrgans (R-iOrgans,) Forward-iOrgans (F-iOrgans) and Drug-iOrgans (D-iOrgans.) They all use iOrgans Indicators (iOrgans-Id) to effectively and efficiently detect the earliest signs of diseases (R-iOrgans,) and to pre-empt them (F-iOrgans.) This technology can be also used to discover effects of drugs (D-iOrgans.) The company was founded by Thomas Sato on October 15, 2015 and is headquartered in Tokyo, Japan. | Director/Board Member | 2015-09-30 |
Allgene, Inc. | Director/Board Member | 2015-11-30 |
Biomedica Solution KK
![]() Biomedica Solution KK BiotechnologyHealth Technology Part of Tella, Inc., Biomedica Solution KK is a Japanese company that manufactures cell production facilities. | Director/Board Member | - |
Former positions of Takehide Iwasa
Companies | Position | End |
---|---|---|
TELLA, INC. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 4 |
---|---|
tella, Inc.
![]() tella, Inc. BiotechnologyHealth Technology tella, Inc. engages in research and development of dendritic cell (DC) vaccine therapy. It operates through the following segments: Cell Medicine, Medical Support, and Pharmaceuticals. The Cell Medicine segment provides cancer treatment technology and know-hows centered on dendritic cell vaccine therapy. The Medical Support segment manages contact research organization (CRO) business and offers genetic testing services. The Pharmaceuticals segment deals with the development of dendritic cell vaccine as a cancer treatment. The company was founded by Yuichiro Yazaki on June 24, 2004 and is headquartered in Tokyo, Japan. | Health Technology |
Karydo TherapeutiX, Inc.
![]() Karydo TherapeutiX, Inc. Miscellaneous Commercial ServicesCommercial Services Karydo TherapeutiX, Inc. develops technologies to detect the earliest signs of diseases. Its proprietary technology includes “iOrgans Technology.” This technology consists of three sub-technologies: Reverse-iOrgans (R-iOrgans,) Forward-iOrgans (F-iOrgans) and Drug-iOrgans (D-iOrgans.) They all use iOrgans Indicators (iOrgans-Id) to effectively and efficiently detect the earliest signs of diseases (R-iOrgans,) and to pre-empt them (F-iOrgans.) This technology can be also used to discover effects of drugs (D-iOrgans.) The company was founded by Thomas Sato on October 15, 2015 and is headquartered in Tokyo, Japan. | Commercial Services |
Allgene, Inc. | |
Biomedica Solution KK
![]() Biomedica Solution KK BiotechnologyHealth Technology Part of Tella, Inc., Biomedica Solution KK is a Japanese company that manufactures cell production facilities. | Health Technology |
- Stock Market
- Insiders
- Takehide Iwasa